Dissociated Tissue & Tumor Cells (DTCs)

Accelerate your precision medicine programs with our biomarker characterized dissociated tumor cells.

View InventoryContact Us
From the team who

First validated cryopreserved tissue dissociations as a viable alternative to fresh cancer tissue samples for research applications.

Discovery’s expert cell services laboratory has evaluated DTCs for many applications through both internal R&D and client partnerships, cultivating unmatched expertise in applying cancer tissue dissociations to custom projects.

DTCs Product Details

Guaranteed Cell Counts

Our Dissociated Tumor Cells (DTCs) and other tissue dissociations are delivered as cryopreserved vials of single cell suspensions with guaranteed cell counts following our Thawing Viable Cell Products protocol.

Tumor, Immune & Stromal Cells

The final tissue dissociation vial will contain ALL of the various cell populations present in the tumor microenvironment.

Proprietary Custom Protocols

With proprietary custom protocols, our scientists have consistently minimized the effects of cryopreservation and demonstrated high percentages of viable cells both pre-freeze (81.3%) and post-thaw (69.7%).

An ideal alternative to fresh tissues without the associated logistical challenges

High cell viability pre-freeze and post-thaw.

Mimics the tumor microenvironment by including tumor, immune and stromal cells

DTCs Featured Resources

White Papers

DTCs Application: Checkpoint Inhibitor Therapy Utilization And PD1/PDL1 Expression Across A Global Clinical Network

Download White Paper

Protocols

View the standard process for thawing viable cell products from cryopreserved dissociated cell suspensions for optimal post-thaw yield.

View Protocol

Presentations

Deep multi-omic phenotyping of biospecimens for immuno-oncology applications.

Watch Video

DTCs Characterizations

Our DTCs are well characterized to aid in precise specimen selection using flow cytometry, NGS, molecular pathology, etc.

Building a Targeted Cohort?

We can further characterize any DTCs samples via multi-omic biomarker services upon request to ensure your study cohorts are optimized for your biomarker targets.

Learn More
Characterization Included on All DTCs:

Base Patient Data

Base patient data and redacted pathology report

Cell Populations

Cell population analysis by flow cytometry

HLA-A02 Status

HLA-A02 status by flow cytometry
Characterization Included on a Subset DTCs:

Targeted Genomic Analysis

A subset of our inventory is characterized by various genomic biomarkers (MSI, EGFR, KRAS, etc.) by PCR or NGS

DTCs Related Matched Sets

Our Discovery Partners® network allows for large-scale, prospective collections of high-quality matched sample sets of human biospecimens.

Each dissociated tumor cell matched sample set is provided with the base clinical data from the patient case, along with cell population analysis and HLA-A02 typing by flow cytometry.

Our scientific team has the knowledge and technical capacity to meet custom requirements and offer laboratory services for matched sample set projects.
DTCs & Sets Report

1000

Unique patient cases available
  • This report includes cell population analysis and HLA-A02 typing by flow cytometry.
  • Mutation/biomarker tested patient samples are listed on a separate tab.
View Sample Report
DTCs + PBMCs

200

Unique patient cases available
  • This report includes cell population analysis and HLA-A02 typing of the DTCs by flow cytometry.
  • Mutation/biomarker tested patient samples (PD-L1, MSI, MMR, BRAF, EGFR, KRAS, and NRAS) are listed on a separate tab within the report.
View Sample Report
DTCs + FFPE

20

Unique patient cases available
  • This report includes cell population analysis and HLA-A02 typing of the DTCs by flow cytometry.
  • Mutation/biomarker tested patient samples (PD-L1, MSI, MMR, BRAF, EGFR, KRAS, and NRAS) are listed on a separate tab within the report.
View Sample Report
DTCs + PBMCs + FFPE

20

Unique patient cases available
  • This report includes cell population analysis and HLA-A02 typing of the DTCs by flow cytometry.
  • Mutation/biomarker tested patient samples (PD-L1, MSI, MMR, BRAF, EGFR, KRAS, and NRAS) are listed on a separate tab within the report.
View Sample Report